Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years - India, 2013 and updates on immunization

Indian Pediatrics

Volumn 50, Issue 12, 2013, Pages 1095-1108

  Vashishtha, Vipin M ^a   Kalra, Ajay ^a   Bose, Anuradha ^a   Choudhury, Panna ^a   Yewale, Vijay N ^a   Bansal, C P ^a   Gupta, Sailesh G ^a  

^a Indian Academy of Pediatrics   (India)

Author keywords

Advisory Committee on Vaccines and Immunization Practices; Immunization Timetable 2013; Indian Academy of Pediatrics; Recommendations

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE;

ARTICLE; EPIDEMIC; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INDIA; INDUSTRIALIZATION; JAPANESE ENCEPHALITIS; MEDICAL SOCIETY; MENINGOCOCCEMIA; PEDIATRICIAN; PERTUSSIS; POLIOMYELITIS VIRUS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTAVIRUS INFECTION; SEROCONVERSION; TYPHOID FEVER;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INDIA; INFANT; PEDIATRICS; VACCINES;

EID: 84891758566     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-013-0292-9     Document Type: Article

References (33)

1. Indian Academy of Pediatrics Committee on Immunization (IAPCOI). Consensus recommendations on immunization and IAP immunization timetable 2012. Indian Pediatr. 2012; 49:549-564.
2. Yewale V, Choudhury P, Thacker N, eds. IAP Guide Book on Immunization. Mumbai: Indian Academy of Pediatrics; 2009-10.
3. Vashishtha VM, Bansal CP, Gupta SG. IAP position paper on pertussis immunization. Indian Pediatr 2013;50:1001-1009.
4. Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ, et al. Effectiveness of pentavalent and rotavuris vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis. 2013;57:13-20.
5. WHO position paper. Rotavirus vaccines. Wkly Epidemiol Rec. 2013;88:49-64.
6. Detailed Review Paper on Rotavirus Vaccines by Ad-hoc group of experts on rotavirus vaccines. Available from: http://www.who.int/immunization/sage/3- Detailed-Review-Paper-on-Rota-Vaccines-17-3-2009.pdf. Accessed on August 8, 2013.
7. Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 2010;28:6542-6548.
8. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289-298.
9. Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine.2012; 30(Suppl 1):A36-43.
10. Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine. 2012;30(Suppl 1):A44-51.
11. Steele AD, Reynders J, Scholtz F, Bos P, de Beer MC, Tumbo J, et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. J Infect Dis. 2010; 202(Suppl):S93-100.
12. Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin. 2009:5;414-9.
13. Lokeshwar MR, Bhave S, Gupta A, Goyal VK, Walia A. Immunogenicity and safety of the pentavalent humanbovine(WC3) reassortment rotavirus vaccine(PRV) in Indian infants. Hum Vaccin Immunother. 2013;9:172-176.
14. Bhandari N, Sharma P, Taneja S, Kumar T, Rangsen-Chandola T, Appaiahgari MB, et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2009; 200: 421-429.
15. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med. 2009;361: 335-344.
16. Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med. 2009; 360:1465-1466.
17. Indian Council of Medical Research. Minutes of the meeting of the Core Committee on Vaccines. Available from: http://www.icmr.nic.in/minutes/ Minutes%20Core%20Committee%20on%20Vaccines.pdf. Accessed on August 11, 2013.
18. Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade C, Kishore T. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine. 2010;28:834-839.
19. Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine. 2008;26:4382-4386.
20. Dubischar-Kastner K, Eder S, Kaltenboeck A, Klade C, Schuller E, Wolfl G. Long term immunity following vaccination with the inactivated Japanese encephalitis vaccine IXIARO and neutralizing antibody response to a booster dose. 11th Conference of the International Society of Travel Medicine; May 24-28, 2009, Budapest, Hungary.
21. Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S. Available from: http://www.vaccines.mil/documents/1624-2013- 21-JEV-pediatric-US-ENG-final.pdf. Accessed on October 3, 2013.
22. ACIP Unanimously Votes to Extend the Recommendations for Use of IXIARO(R) Vaccine. Available from: http://www.reuters.com/article/2013/06/21/ idUSnHUGd8N0+72+ONE20130621. Accessed on October 3, 2013.
23. Dubischar-Kastner K, Eder S, Kaltenboeck A, Klade C, Schuller E, Wolfl G. Safety and immunogenicity of the inactivated Japanese encephalitis vaccine IXIARO®, IC51, in Filipino Children aged 2 months to <18 years. Presented at the 4th Northern European Conference on Travel Medicine, June 2012, Abstract P.9. Available at http://nectm.com/wpcontent/uploads/BookofAbstracts.pdf. Accessed on August 12, 2013.
24. Dubischar-Kastner K, Eder S, Kaltenboeck A, Klade C, Schuller E, Wolfl G. Interim safety and immunogenicity data for the inactivated Japanese encephalitis vaccine IXIARO®, IC51, in Children from JE non-endemic countries. Presented at the 4th Northern European Conference on Travel Medicine, June 2012, Abstract P.9. Available at http://nectm.com/wp-content/uploads/ BookofAbstracts.pdf. Accessed on August 12, 2013.
25. Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011; 30:451-455.
26. Grading of scientific evidence - Table VI a & b (efficacy of quadrivalent meningococcal conjugate vaccines). Available at http://www.who.int/entity/immunization/meningococcal-grad-efficacy.pdf. Accessed on August 14, 2013.
27. Kroger A. General Recommendations on Immunization. ACIP Presentation Slides: February 2013 Meeting. Available from: http://www.cdc.gov/vaccines/acip/ meetings/downloads/slides-feb-2013/02-GenRecs-Kroger.pdf Accessed on August 16, 2013.
28. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011; 86:521-539.
29. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi MP, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007; 25(Suppl 1):A101-107.
30. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011;364:2293-2304.
31. Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi MP, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine. 2012;30:6456-6460.
32. Grading of scientific evidence - Table IV a & b (efficacy of MenA conjugate vaccine). Available from: http://www.who.int/entity/immunization/ meningococcalA-grad-efficacity.pdf. Accessed on August 16, 2013.
33. Sinclair D, Preziosi MP, John TJ, Greenwood B. The epidemiology of meningococcal disease in India. Trop Med Int Health. 2010;15:1421-1435.